×
Enlivex Therapeutics EBITDA 2013-2025 | ENLV
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Enlivex Therapeutics ebitda from 2013 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
View More
Enlivex Therapeutics EBITDA 2013-2025 | ENLV
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Enlivex Therapeutics ebitda from 2013 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company Name
Market
Cap
Chugai Pharmaceutical (CHGCY)
$81.7B
Zoetis (ZTS)
$67.1B
Daiichi Sankyo, - (DSNKY)
$46.4B
Takeda Pharmaceutical (TAK)
$45.5B
BeOne Medicines - (ONC)
$32.3B
Sandoz Group AG (SDZNY)
$26.1B
Summit Therapeutics (SMMT)
$20.4B
Merck (MKKGY)
$16.9B
Shionogi (SGIOY)
$15B
United Therapeutics (UTHR)
$13.4B
Neurocrine Biosciences (NBIX)
$13.2B
Orion OYJ (ORINY)
$11.5B
IPSEN (IPSEY)
$10.8B
Stevanato Group S.p.A (STVN)
$7.9B
Corcept Therapeutics (CORT)
$7.3B
Grifols, S.A (GRFS)
$6.9B
Ionis Pharmaceuticals (IONS)
$6.6B
Madrigal Pharmaceuticals (MDGL)
$6.5B
Hikma Pharmaceuticals Plc (HKMPF)
$6.2B
Ono Pharmaceutical (OPHLF)
$5.2B
Soleno Therapeutics (SLNO)
$4.3B
Hypermarcas (HYPMY)
$3B
Crinetics Pharmaceuticals (CRNX)
$2.8B
NewAmsterdam Pharma (NAMS)
$2.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.6B
Catalyst Pharmaceuticals (CPRX)
$2.5B
Centessa Pharmaceuticals (CNTA)
$2B
Ocular Therapeutix (OCUL)
$1.9B
Endo (NDOI)
$1.8B
ARS Pharmaceuticals (SPRY)
$1.8B